Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

References

• PetersonGEIntermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemirCurr Med Res Opin2006222613261917166343
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe absence of a glycemic threshold for the development of long-term complicationsDiabetes199645128912988826962
   PubMed Web of Science ®Google Scholar
• ReichardOThe effect of long-term intensified insulin treatment of microvascular complications of diabetes mellitusN Engl J Med19933293043098147960
   PubMed Web of Science ®Google Scholar
• WangPHMeta-analysis of effects of intensive blood-glucose control on late complications of type I diabetesLancet1993341130613098098449
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupHypoglycemia in the Diabetes Control and Complications TrialDiabetes1997462712869000705
   PubMed Web of Science ®Google Scholar
• NathanDMIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med2005353252643265316371630
   PubMed Web of Science ®Google Scholar
• StrattonIMAssociation with glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational studyBMJ200032140541210938048
   PubMed Web of Science ®Google Scholar
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesThe Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research GroupN Engl J Med20053532643265316371630
   PubMed Web of Science ®Google Scholar
• GædePIntensive integrated therapy of type 2 diabetes: implications for long-term prognosisDiabetes200453S39S4715561920
   PubMed Web of Science ®Google Scholar
• BloomgardenZTGlycemic control in diabetes: a tale of three studiesDiabetes Care2008311913191918753670
   PubMed Web of Science ®Google Scholar
• WrightASulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57)Diabetes Care20022533033611815505
   PubMed Web of Science ®Google Scholar
• DluhyRGIntensive Glycemic Control in the ACCORD and ADVANCE TrialsN Engl J Med20083582630263318539918
   PubMed Web of Science ®Google Scholar
• HirschIBShould minimal blood glucose variability become the gold standard of glycemic control?J Diabetes Complicat20051917818115866065
   PubMed Web of Science ®Google Scholar
• UngerJReducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to actionInsulin200833176184
   Google Scholar
• RendellMSTargeting postprandial hyperglycemiaMetabolism2006551263128116919548
   PubMed Web of Science ®Google Scholar
• Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind controlled trialPediatr Diabetes2008938238718331413
   PubMed Web of Science ®Google Scholar
• DanneTInsulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetesDiabetes Care2003263087309214578244
   PubMed Web of Science ®Google Scholar
• Le FlochJPA comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT)Diabetes Care200932323718945928
   PubMed Web of Science ®Google Scholar
• HomePInsulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes: a randomized clinical trialDiabetes Care2004271081108715111525
   PubMed Web of Science ®Google Scholar
• Russell-JonesDEffects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimenClin Ther20042672473615220016
   PubMed Web of Science ®Google Scholar
• RobertsonKBenefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemiaDiabetes200453Suppl 2A144
   Google Scholar
• HermansenKInsulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetesDiabetologia20044762262915298338
   PubMed Web of Science ®Google Scholar
• KolendorfKInsulin detemir is associated with lower risk of hypoglycemia than NPH insulin in people with type 1 diabetesDiabetes200453Suppl 1A130
   Google Scholar
• PieberTRComparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulinDiabetic Med20052285085715975098
   PubMed Web of Science ®Google Scholar
• HaakTLower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes Obes Metab20057566415642076
   PubMed Web of Science ®Google Scholar
• RaslovaKInsulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetesDiabetes Res Clin Pract20046619320115533587
   PubMed Web of Science ®Google Scholar
• HermansenKA 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with Type 2 diabetesDiabetes Care2006291269127416732007
   PubMed Web of Science ®Google Scholar
• MeneghiniLFInsulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyDiabetes Obes Metab2007941842717391170
   PubMed Web of Science ®Google Scholar
• MeneghiniLEfficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes suing a simplified self-adjusted dosing guideline – results of the PREDICTIVE 303 study Program and abstracts of the 67th Scientific Sessions of the American Diabetes Association June 22–26, 2007 Chicago, Illinois Abstract 197-OR
   Google Scholar
• RosenstockJA randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naïve people with Type 2 diabetesDiabetologia20085140841618204830
   PubMed Web of Science ®Google Scholar
• Fajardo MontananaCLess weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trialDiabet Med200825891692318959604
   PubMed Web of Science ®Google Scholar
• PetersonGEInsulin detemir in type 1 and type 2 diabetes [abstract] Ehrlich II World Congress Nurenberg, Germany October 2008
   Google Scholar